REFERENCES
- Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52: 1551–1557.
- Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the result of 20 years of follow-up. N Engl J Med 1995; 332: 901–906.
- Veronesi U, Valagussa P. Inefficacy of internal mamma-ry nodes dissection in breast cancer surgery. Cancer 1981; 47: 170–175.
- Bull JM, Tormey DC, Li S, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649–1657.
- French Epirubicin Study Group. A prospective random-ized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679–688.
- Italian Multicenter Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin and cyclophos-phamide in advanced breast cancer. An Italian multicenter trial. J Clin Oncol 1988; 6: 976–982.
- Coombes RC, Bliss JM, Wits J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluo-rouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996; 14: 35–45.
- Misset JL, di Palma M, Delgado M, et al. Adjuvant treat-ment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophos-phamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14: 1136–1145.
- Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophos-phamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651–2658.
- Kanno M, Nakamura S, Uotani C, et al. Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study. J Chemother 1999; 11: 396–401.
- Bezwoda WR, Hesdorffer CS. Mitoxantrone, methotrexate, and 5-fluorouracil combination chemotherapy as first-line treatment in stage IV breast cancer. Cancer 1986; 57: 218–221.
- Fountzilas G, Polichronis A, Katsohis K, et al. Cyclophosphamide, mitoxantrone, fluorouracil versus conven-tional CMF as adjuvant treatment in node-positive breast can-cer patients. A Hellenic Cooperative Oncology Group Study. Oncology 1996; 53: 137–146.
- Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA. Mitoxantrone, 5-fluorouracil, and high dose leukovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma. Cancer 1997; 79: 740–748.
- Urban JA, Castro EB. Selecting variations in extent of surgical procedures for breast cancer. Cancer 1971; 28: 1615–1623.
- Veronesi U, Cascinelli N, Greco M, et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985; 202: 702–707.
- Cody HS 3rd, Urban JA. Internal mammary node sta-tus: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995; 2: 32–37.
- Noguchi M, Koyasaki N, Ohta N, et al. Internal mam-mary nodal status is more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer. Arch Surg 1993; 128: 242–246.
- Ege GN, Elhakim T. The relevance of internal mamma-ry lymphoscintigraphy in the management of breast carcino-ma. J Clin Oncol 1984; 2: 774–781.
- Noguchi M, Kawahara F, Tsugawa K, et al. Sentinel lymphadenectomy in breast cancer: An alternative to routine axillary dissection. Breast Cancer 1998; 5: 1–6.
- Rodenhuis S, Richel DJ, van der Wall E, et al. Randomized trial of high-dose chemotherapy and haematopoi-etic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515–521.
- O'Leary J, Volm M, Wasserheit C, Muggia F. Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology 1998; 12 (Suppl 1): 23–27.
- Nabholtz JM, Mackey J, Smylie M, Tonkin K. Taxane-based three-drug combination in metastatic and adjuvant treat-ment of breast cancer. Semin Oncol 1998; 25 (Suppl 12): 27–31.